BioCryst Pharmaceuticals BCRX Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's reclassification from accumulated other comprehensive income, current period, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's reclassification from accumulated other comprehensive income, current period, before tax?
- BioCryst Pharmaceuticals (BCRX) reported reclassification from accumulated other comprehensive income, current period, before tax of $0 in Q1 2026.
- What is the long-term trend for BioCryst Pharmaceuticals's reclassification from accumulated other comprehensive income, current period, before tax?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's reclassification from accumulated other comprehensive income, current period, before tax has grown at a -100.0% compound annual growth rate (CAGR), from $1K to $0.
- What does reclassification from accumulated other comprehensive income, current period, before tax mean?
- This represents the amount of gains or losses previously recorded in accumulated other comprehensive income that are reclassified into net income during the current period. It reflects the realization of items such as foreign currency translation adjustments or unrealized gains on securities that now impact the income statement. Monitoring this helps investors understand the volatility of earnings driven by non-operating accounting adjustments.